medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number 02

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (02)

Incidence of genetic mutations in patients with breast cancer and ovarian cancer with hereditary pattern

Ulloa-Miranda MÁ, Sánchez-Forgach ER, Sánchez-Aguirre F, Hernández-Valencia M, Hernández-Hernández DI, Rosas-Luna M, Ramírez-Gómez JI

Language: Spanish
References: 19
Page: 92-97
PDF size: 186.25 Kb.


ABSTRACT

Objective: To determine the genetic mutations in hereditary pattern breast cancer and demonstrate whether there is a significant association between the most common in the Mexican population and the risk of suffering it.
Materials and Methods: Cross-sectional and observational study conducted at the Hospital Angeles México in coordination with the National Institute of Genomic Medicine. Inclusion criteria: patients with breast cancer and one or more first-degree relatives affected by this disease and patients with ovarian cancer. Exclusion criteria: patients without a history of breast or ovarian cancer, or with a family member in the protocol. The RT2 Profiler plate rearrangement technique was used for Master-Mix Quantinova probe PCR kit. The SPSS version 22 program and Epi Info version 7 were used for the statistical analysis.
Results: 39 patients with an average age of 53.2 ± 12.1 years were studied. Progesterone and estrogen receptors showed no difference between groups. There was a greater trend for BRCA1. When studying the mutations with statistical significance, in which the cases of BRCA2 versus without significance and the negative cases stood out, there was no significant statistical difference, but with a tendency to higher frequency of BCRA1. When evaluating breast cancer lines and nuclear grades compared by age, the three nuclear grade groups compared by age showed differences.
Conclusion: The data obtained show that in the Mexican population the BRCA2 gene has a higher incidence in hereditary cancer, at an age of earlier onset and greater nuclear grade at the time of diagnosis.


REFERENCES

  1. Vidal-Millán S. Cáncer de mama hereditario: identificación y elección de pacientes para estudio molecular de los genes BRCA; Cancerología 2008; 3: 51-61. http://incanmexico. org/revistainvestiga/elementos/documentosPortada/ 1215567331.pdf2.

  2. Rowley JD, et al. The impact of new DNA diagnostic technology on the management of cancer patients Survey of diagnostic techniques. Arch Pathol Lab Med. 1993; 117: 1104-9. PMID: 8239930

  3. Malkin D, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990. 30; 250: 1233-38. doi: 10.1126/ science.1978757

  4. Ribnikar D, et al. General Overview and Treatment Recommendations for Young Women with Breast Cancer. Rev Inves Clin. 2017; 69:77-93. http://www.medigraphic. com/pdfs/revinvcli/nn-2017/nn172d.pdf5.

  5. Herrera Gómez NS, et al. Manual de Oncología, Procedimientos Médico Quirúrgicos. 6ª ed. México: McGrawHill, 2017.

  6. Weber BL. Cancer Genomics. Cancer Cell 2002;1 (1): 37- 47 https://www.ncbi.nlm.nih.gov/pubmed/12086886. https://doi.org/10.1016/S1535-6108(02)00026-0

  7. Statement of the American Society of Clinical Oncology. Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736, 1996

  8. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406, 2003. DOI: 10.1200/JCO.2009.27.0660

  9. Robson ME, Storm CD, Weitzel J. American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. J Clin Oncol 28:893-901, 2010. doi: 10.1200/JCO.2015.63.0996

  10. Robson ME, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 33. doi:10.1200/ JCO.2015.63.3628

  11. Hall JM, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-89. doi.10.1126/science.2270482

  12. Easton DF, et al. Breast and ovarian cancer incidence in BRCA1- mutation carriers; Am J Hum Genet. 1995; 56: 265-71. 7825587

  13. Wooster R, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378: 789-92. https:// doi.org/10.1038/378789a0

  14. Gayther SA, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997, 15: 103-105. https:// doi.org/10.1038/ng0197-103

  15. Bork P, et al. Internal repeats in the BRCA2 protein sequence. Nat Genet. 1996; 13: 22-23. https://doi.org/10.1038/ng0596-22

  16. Bignell G, et al. The BRC repeats are conserved in mammalian BRCA2 proteins. Hum Mol Genet. 1997; 6: 53-58. https://doi.org/10.1093/hmg/6.1.53

  17. Phang-Lang Chen, et alThe BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. PNAS 1998; 95:5287-5292. https://doi. org/10.1073/pnas.95.9.5287

  18. Wong AKC, et al. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2; J Biol Chem. 1997; 272: 31941-44. doi: 10.1074/jbc.272.51.31941

  19. Ruiz de Garibay Ponce G. Síndromes hereditarios de cáncer de mama familiar: variantes de significado clínico incierto y consejo genético. Universidad Complutense, Facultad de Farmacia, Departamento De Bioquímica y Biología Molecular II. Madrid, España, 2014.




2020     |     www.medigraphic.com